JULIE GASTIER-FOSTER to Wilms Tumor
This is a "connection" page, showing publications JULIE GASTIER-FOSTER has written about Wilms Tumor.
Connection Strength
0.931
-
Augmentation of Therapy for Combined Loss of Heterozygosity 1p and 16q in Favorable Histology Wilms Tumor: A Children's Oncology Group AREN0532 and AREN0533 Study Report. J Clin Oncol. 2019 10 20; 37(30):2769-2777.
Score: 0.149
-
Treatment of Stage IV Favorable Histology Wilms Tumor With Lung Metastases: A Report From the Children's Oncology Group AREN0533 Study. J Clin Oncol. 2018 06 01; 36(16):1564-1570.
Score: 0.135
-
Reply to B. Zhang et al. J Clin Oncol. 2018 05 10; 36(14):1454-1455.
Score: 0.135
-
A Children's Oncology Group and TARGET initiative exploring the genetic landscape of Wilms tumor. Nat Genet. 2017 10; 49(10):1487-1494.
Score: 0.129
-
Significance of TP53 Mutation in Wilms Tumors with Diffuse Anaplasia: A Report from the Children's Oncology Group. Clin Cancer Res. 2016 Nov 15; 22(22):5582-5591.
Score: 0.122
-
MLLT1 YEATS domain mutations in clinically distinctive Favourable Histology Wilms tumours. Nat Commun. 2015 Dec 04; 6:10013.
Score: 0.115
-
Recurrent DGCR8, DROSHA, and SIX homeodomain mutations in favorable histology Wilms tumors. Cancer Cell. 2015 Feb 09; 27(2):286-97.
Score: 0.108
-
Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design. Cell Rep. 2019 11 05; 29(6):1675-1689.e9.
Score: 0.038